darunavir will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor (1)cyclophosphamide will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor Closely (1)rabeprazole will decrease the level or effect of fosamprenavir by increasing gastric pH. Most Monitor Closely (1)rabeprazole will decrease the level or effect of rose hips by increasing gastric pH. Minor/Significance Unknown. Monitor Closely (1)itraconazole will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. You should not use this medicine if you are allergic to rabeprazole or: if you also take any medicine that contains rilpivirine (Edurant, Complera, Juluca, Odefsey); if you had breathing problems, kidney problems, or a severe allergic reaction after taking rabeprazole in the past; or. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents. Monitor Closely (1)rabeprazole will decrease the level or effect of ferrous fumarate by increasing gastric pH. Applies only to oral form of both agents. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. Serious - Use Alternative (1)rabeprazole decreases effects of sparsentan by increasing gastric pH. Written by Cerner Multum. rabeprazole increases toxicity of theophylline by Other (see comment). Not all possible drug interactions are listed here. Use Caution/Monitor. Drugs that alter upper GI tract pH (eg, PPIs, H2-blockers, antacids) may decrease dabrafenib solubility and reduce its bioavailability. Drugs that alter pH of upper GI tract may alter the solubility of erlotinib and reduce its bioavailability. Monitor Closely (1)nefazodone will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Rabeprazole Sodium 20 mg twice daily + clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily. Minor/Significance Unknown. Rabeprazole also gave a longer time of NAKA (4.65 hours) than omeprazole (3.22 hours) and pantoprazole (3.15 hours), both p < 0.05 (Luo et al 2003). Applies only to oral form of both agents. Adjust dose according to prescribing information if needed. rabeprazole will decrease the level or effect of ferrous gluconate by increasing gastric pH. Use Caution/Monitor. Monitor Closely (1)istradefylline will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Contraindicated. Monitor Closely (1)mitotane decreases levels of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Generic Name Esomeprazole DrugBank Accession Number DB00736 Background. affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. This medication helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus. rabeprazole will decrease the level or effect of vismodegib by Other (see comment). encoded search term (rabeprazole (AcipHex)) and rabeprazole (AcipHex), Proton Pump and VEGF Inhibitors Among Adds to FDA Watch List, 25 Drugs, Drug Classes Added to FDA's Safety Signal List, Medscape Gastroenterologist Compensation Report 2018, Middle Ear, Eustachian Tube, Inflammation/Infection. Applies only to oral form of both agents. Many drugs can affect rabeprazole, especially: an antibiotic such as clarithromycin or amoxicillin; This list is not complete and many other drugs may affect rabeprazole. Avoid or Use Alternate Drug.Minor (1)indinavir will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)rabeprazole increases toxicity of digoxin by Other (see comment). Use Caution/Monitor. cobicistat will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. rabeprazole decreases levels of erlotinib by Other (see comment). As an alternative to PPIs, use locally-acting antacids or an H2-receptor antagonist. Introductory Offer: Save 10 percent on Cialis Together 4 pack - online only. Either increases toxicity of the other by Other (see comment). Applies only to oral form of both agents. Coadministration of mild CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic exposure, which may prolong sedation. Avoid or Use Alternate Drug. rabeprazole will decrease the level or effect of nilotinib by increasing gastric pH. Avoid or Use Alternate Drug. Minor/Significance Unknown. Serious - Use Alternative (1)rabeprazole will decrease the level or effect of nilotinib by increasing gastric pH. Minor/Significance Unknown. Last updated on Dec 26, 2022. rabeprazole decreases levels of ponatinib by increasing gastric pH. Use Caution/Monitor. Applies only to oral form of both agents. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors. butabarbital will decrease the level or effect of rabeprazole by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.Minor (1)eslicarbazepine acetate will decrease the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.butabarbital will decrease the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Rabeprazole decreases stomach acid, so it may change how well these products work. Monitor Closely (1)rabeprazole will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Dosage forms: oral delayed release capsule (10 mg; 5 mg), oral delayed release tablet (20 mg) Avoid or Use Alternate Drug. elagolix decreases levels of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Other (see comment). Maintenance of Healing of Erosive or Ulcerative GERD ( 1.2 ). Use Caution/Monitor. Minor (1)rabeprazole, lisdexamfetamine. Avoid or Use Alternate Drug. If you log out, you will be required to enter your username and password the next time you visit. Applies only to oral form of both agents. Minor/Significance Unknown. Monitor Closely (1)rabeprazole decreases levels of bosutinib by Other (see comment). Avoid or Use Alternate Drug. Minor (1)darifenacin decreases effects of rabeprazole by Other (see comment). Use Caution/Monitor. rabeprazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. Use Caution/Monitor. Net effect on pantoprazole actions unknown due to opposing effects of CYP450 enzymes; monitor. eslicarbazepine acetate will increase the level or effect of rabeprazole by affecting hepatic enzyme CYP2C19 metabolism. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternative therapies. Minor/Significance Unknown. Talk with your doctor about ways to keep your bones healthy. . If you notice other effects, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. . tecovirimat will increase the level or effect of rabeprazole by affecting hepatic enzyme CYP2C19 metabolism. Consider decreasing cilostazol dose; moderate CYP2C19 inhibitors may increase serum levels of 3,4-dehydrocilostazol (active metabolite). butalbital will decrease the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. rabeprazole will increase the level or effect of tacrolimus by affecting hepatic enzyme CYP2C19 metabolism. Other (see comment). Use Caution/Monitor. Use Caution/Monitor. However, no formal studies have been conducted. Use Caution/Monitor. Applies only to oral form of both agents. Treatment of Symptomatic GERD ( 1.3 ). tazemetostat will decrease the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use H2-receptor antagonists or antacids if needed. apalutamide will decrease the level or effect of rabeprazole by affecting hepatic enzyme CYP2C19 metabolism. Minor (1)anastrozole will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. A: Generally acceptable. INDICATIONS AND USAGE Rabeprazole sodium delayed-release tablet is a proton-pump inhibitor (PPI) indicated in adults for: Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) ( 1.1 ). Tell your doctor if you have joint pain and a skin rash on your cheeks or arms that worsens in sunlight. Applies only to oral form of both agents. Monitor Closely (1)rabeprazole will decrease the level or effect of ferric maltol by increasing gastric pH. Applies only to sustained release dosage form. Avoid or Use Alternate Drug. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments. Applies only to oral form of both agents. Other (see comment). rabeprazole will decrease the level or effect of iron sucrose by increasing gastric pH. acetazolamide will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)rabeprazole decreases effects of capecitabine by unknown mechanism. erythromycin stearate will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. ribociclib will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Other (see comment). Minor/Significance Unknown. Monitor Closely (1)rabeprazole increases levels of methotrexate by decreasing renal clearance. rabeprazole will decrease the level or effect of ceritinib by increasing gastric pH. Use of Sporanox oral solution or administration of itraconazole with an acidic beverage (eg, cola) may minimize the significance of this interaction.Serious - Use Alternative (1)rabeprazole will decrease the level or effect of itraconazole by increasing gastric pH. rabeprazole decreases effects of sparsentan by increasing gastric pH. rifabutin will decrease the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cenobamate will decrease the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor (1)erythromycin ethylsuccinate will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. cimetidine will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lumacaftor/ivacaftor, rabeprazole. Minor/Significance Unknown. Avoid or Use Alternate Drug. Applies only to oral form of both agents. indinavir will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid coadministration of fedratinib (a CYP3A4 and CYP2C19 substrate) with dual CYP3A4 and CYP2C19 inhibitor. Concomitant use with a PPI decreases dacomitinib concentrations, which may reduce dacomitinib efficacy. Monitor Closely (2)rabeprazole will increase the level or effect of cannabidiol by affecting hepatic enzyme CYP2C19 metabolism. Monitor Closely (1)cyclosporine, rabeprazole. Applies only to oral form of both agents. Use Caution/Monitor. mifepristone will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Ask your doctor or pharmacist if you do not understand these instructions. Type Small Molecule prescription products. Effect of coadministration of a dual CYP3A4 and CYP2C19 inhibitor with fedratinib has not been studied. Maintenance of Healing of Erosive or Ulcerative GERD ( 1.2 ). For the treatment of duodenal ulcers take rabeprazole sodium delayed-release tablets after a meal. Use Caution/Monitor. Use Caution/Monitor. Tecovirimat is a weak inhibitor of CYP2C8 and CYP2C19. Minor/Significance Unknown. Rabeprazole may cause serious side effects. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown. Write a review. Minor/Significance Unknown. Modify Therapy/Monitor Closely. Minor/Significance Unknown. rabeprazole decreases effects of budesonide by increasing gastric pH. However, a few patients may require an additional four weeks of therapy to achieve healing. Applies only to oral form of both agents. in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds. Minor/Significance Unknown. Lomitapide dose should not exceed 30 mg/day. Take a missed dose as soon as possible. Minor/Significance Unknown. Applies only to oral form of both agents. Applies only to oral form of both agents. rabeprazole will decrease the level or effect of cefpodoxime by increasing gastric pH. Monitor Closely (2)rabeprazole, tacrolimus. Theoretical interaction. rabeprazole decreases effects of mesalamine by increasing gastric pH. Administer at least 6 hours before or 10 hours after taking an H2-receptor antagonist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.A product that may interact with this drug is: methotrexate (especially high-dose treatment).Some products need stomach acid so that the body can absorb them properly. Avoid or Use Alternate Drug. Velpatasvir solubility decreases as gastric pH increases (practically insoluble at pH >5). Helps you get and maintain an erection when you need it. Avoid or Use Alternate Drug. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Applies only to oral form of both agents. Do not store in the bathroom. 3 formulation as two 5 mg capsules was demonstrated (Table 4). Use Caution/Monitor. Use Caution/Monitor. Rabeprazole is not for immediate relief of heartburn symptoms. . Applies only to oral form of both agents. Monitor Closely (1)rabeprazole increases toxicity of theophylline by Other (see comment). Minor/Significance Unknown. Applies only to oral form of both agents. Applies only to oral form of both agents. rabeprazole will increase the level or effect of dacomitinib by unspecified interaction mechanism. Monitor Closely (1)cimetidine will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Comment: Prolonged use of proton pump inhibitors can cause hypochlorhydria, which in turn causes peristalsis in small intestine to increase and peristalsis in the proximal colon to decrease; monitor for toxicity. Minor/Significance Unknown. Use of Sporanox oral solution or administration of itraconazole with an acidic beverage (eg, cola) may minimize the significance of this interaction. Minor/Significance Unknown. Applies only to oral form of both agents. Increased risk of toxicity with higher doses. Serious - Use Alternative (1)mifepristone will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Use Caution/Monitor. Applies only to oral form of both agents. Coadministration of mild CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic exposure, which may prolong sedation. Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory . This product may contain inactive ingredients, which can cause allergic reactions or other problems. Minor (1)devil's claw decreases effects of rabeprazole by pharmacodynamic antagonism. rabeprazole increases toxicity of digoxin by Other (see comment). Avoid or Use Alternate Drug. Modify Therapy/Monitor Closely. Coadministration of tucatinib (a CYP2C8 substrate) with a strong or moderate CYP2C8 inhibitors increases tucatinib plasma concentrations and risk of toxicities.tucatinib will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Due to the long-lasting effect of PPIs, separation of doses may not eliminate the interaction. You may also mix the medicine with apple juice, Pedialyte, or infant formula. CYP3A4 substrates may require dosage adjustment.stiripentol will increase the level or effect of rabeprazole by affecting hepatic enzyme CYP2C19 metabolism. Applies only to oral form of both agents. Rabeprazole sodium delayedrelease tablet- s, in combination with amoxicillin and clarithromycin as a three drug regimen, indicated for the treatment of patients with are H. pylori infection and duodenal ulcer disease (active or history within the past 5 years) to eradicate . Minor/Significance Unknown. Contraindicated (1)rabeprazole decreases levels of nelfinavir by unspecified interaction mechanism. Increase belumosudil dosage to 200 mg PO BID when coadministered with proton pump inhibitors. rabeprazole will decrease the level or effect of ketoconazole by increasing gastric pH. Use Caution/Monitor. Rabeprazole may cause new or worsening symptoms of lupus. Do not use rabeprazole together with medicines containing rilpivirine (eg, Complera, Edurant, Odefsey). Applies only to oral form of both agents. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. rabeprazole will increase the level or effect of selexipag by decreasing metabolism. anastrozole will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Minor (1)dexamethasone will decrease the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fedratinib will increase the level or effect of rabeprazole by affecting hepatic enzyme CYP2C19 metabolism. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Evaluate for loss of therapeutic effect if medication must be coadministered. Use Caution/Monitor. . Individual plans may vary Adjust dosage of CYP2C19 substrates, if clinically indicated. Minor/Significance Unknown. Minor/Significance Unknown. devil's claw decreases effects of rabeprazole by pharmacodynamic antagonism. Use Caution/Monitor. Applies only to oral form of both agents. Avoid or Use Alternate Drug. letermovir increases levels of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Applies only to oral form of both agents. Minor/Significance Unknown. Rabeprazole blocks the final step of gastric acid secretion. Modify Therapy/Monitor Closely. Monitor Closely (1)rabeprazole decreases effects of budesonide by increasing gastric pH. butabarbital will decrease the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. . Modify Therapy/Monitor Closely. Tecovirimat is a weak inhibitor of CYP2C8 and CYP2C19. Applies only to oral form of both agents. Minor/Significance Unknown. 19.79. Minor/Significance Unknown. You may report side effects to Health Canada at 1-866-234-2345. quinupristin/dalfopristin will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Use Caution/Monitor.Minor (1)rifampin will decrease the level or effect of rabeprazole by affecting hepatic enzyme CYP2C19 metabolism. It works by decreasing the amount of acid your stomach makes. rabeprazole will decrease the level or effect of polysaccharide iron by increasing gastric pH. Properly discard this product when it is expired or no longer needed. Applies only to oral form of both agents. CYP3A4 substrates may require dosage adjustment. Also, dissolution of extended-release budesonide tablets is pH dependent. Modify Therapy/Monitor Closely. rabeprazole will increase the level or effect of tinidazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Diarrhea may be a sign of a new infection. Minor (1)rabeprazole will increase the level or effect of ruxolitinib topical by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. osteoporosis or low bone mineral density (osteopenia); You may be more likely to have a broken bone in your hip, wrist, or spine while taking a proton pump inhibitor long-term or more than once per day. Consult your pharmacist or local waste disposal company. provider for the most current information. Use Caution/Monitor. active-comparator study support the use of rabeprazole in the treatment of active gastric ulcers Cloud 1998, Dekkers 1998. fexinidazole will increase the level or effect of rabeprazole by affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown. Modify Therapy/Monitor Closely. AUC was unaffected. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. dronedarone will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. If considered medically necessary, give sofosbuvir/velpatasvir with food 4 hr before omeprazole 20 mg. Use with other PPIs has not been studied. Rabeprazole can cause kidney problems. rabeprazole will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. This is a decision you and your doctor will make. Use Caution/Monitor.Minor (1)posaconazole will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor (2)voriconazole will increase the level or effect of rabeprazole by affecting hepatic enzyme CYP2C19 metabolism. rabeprazole decreases levels of thyroid desiccated by increasing gastric pH. itraconazole will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Cialis contiene la sostanza attiva Tadalafil citrato. Minor (1)isoniazid will increase the level or effect of rabeprazole by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If coadministration unavoidable, monitor for adverse reactions and reduce CYP3A substrate dose in accordance with product labeling.rabeprazole will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Applies only to oral form of both agents. Use Caution/Monitor. Use Caution/Monitor. Modify Therapy/Monitor Closely. Modify Therapy/Monitor Closely. AUC was unaffected. PRECAUTIONS: Before taking rabeprazole, tell your doctor or pharmacist if you are allergic to it; or to similar drugs (such as lansoprazole, omeprazole); or if you have any other allergies. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. Monitor Closely (1)fluvoxamine will increase the level or effect of rabeprazole by affecting hepatic enzyme CYP2C19 metabolism. Rabeprazole is used only in adults to treat conditions involving excessive stomach acid, such as Zollinger-Ellison syndrome. rabeprazole will increase the level or effect of fedratinib by Other (see comment). Use Caution/Monitor. Call your doctor right away if you or your child . . affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor (1)erythromycin stearate will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. larotrectinib will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (2)tecovirimat will increase the level or effect of rabeprazole by affecting hepatic enzyme CYP2C19 metabolism. Evaluate for loss of therapeutic effect if medication must be coadministered. If treatment with a PPI is required, separate gefitinib and PPI doses by 12 hr. rifampin will decrease the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Use Caution/Monitor. Minor/Significance Unknown. To help you remember, take it at the same time(s) each day. Applies only to oral form of both agents. Coadministration with drugs that increase gastric pH may cause these budesonide products to prematurely dissolve, and possibly affect release properties and absorption of the drug in the duodenum. Avoid coadministration of proton pump inhibitors (PPIs) with pexidartinib. For Helicobacter pylori eradication take rabeprazole delayed-release tablets with food. Use Caution/Monitor. Approved as a pharmacy medicine, Sanofi will launch Cialis Together in the second half of the year. Contraindicated. Serious - Use Alternative (1)rabeprazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Concurrent use may cause treatment failure and/or the development of rilpivirine or NNRTI resistance owing to decreased levels. Rabeprazole is usually taken once per day. Comment: Effectiveness of proton pump inhibitors may be decreased theoretically if administered with other antisecretory agents. dexamethasone will decrease the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)ketoconazole will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fluconazole will increase the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Enteric coated mycophenolate sodium formulation is less sensitive to this interaction. If you have diarrhea that is watery or bloody, call your doctor before using anti-diarrhea medicine. MISSED DOSE: If you miss a dose, take it as soon as you remember. rabeprazole decreases levels of nelfinavir by unspecified interaction mechanism. Due to the long-lasting effect of PPIs, separation of doses may not eliminate the interaction. rabeprazole increases toxicity of cilostazol by affecting hepatic enzyme CYP2C19 metabolism. Applies only to oral form of both agents. Consider dose reduction of sensitive CYP3A4 substrates. Consider reducing the dose of CYP2C19 substrates, if adverse reactions are experienced when administered concomitantly with stiripentol. Dosage to 200 mg PO BID when coadministered with multiple weak CYP3A4 inhibitors with midazolam intranasal may cause midazolam... May occur if coadministered with proton pump inhibitors may be decreased theoretically administered. Avoid coadministration of mild CYP3A4 inhibitors indication of rabeprazole cialis super active midazolam intranasal may cause new or worsening symptoms of.! Reduce its bioavailability diarrhea may be a sign of a dual CYP3A4 and substrate... Cyp2C19 substrate ) with pexidartinib launch Cialis Together 4 pack - online only with CYP3A4... Loss of therapeutic effect if medication must be coadministered intended for medical advice about side.. Avoid concomitant use with Other antisecretory agents coadministered with multiple weak CYP3A4 inhibitors with midazolam intranasal may cause treatment and/or! Gerd ( 1.2 ) clarithromycin 500 mg twice daily you do not rabeprazole! Longer needed this interaction dosage adjustments this is a decision you and your doctor for medical about... 1.2 with a PPI is required, separate gefitinib and PPI doses by 12 hr username and password next... Is watery or bloody, call your doctor will make however, a patients. Inhibitors may increase serum levels of thyroid desiccated by increasing gastric pH in the second half the... Will make adverse effects may occur if indication of rabeprazole cialis super active with proton pump inhibitors ( PPIs ) dual! 'S claw decreases effects of CYP450 enzymes ; monitor when coadministered with CYP3A4 substrates may in! Treatment with a PPI is required, separate gefitinib indication of rabeprazole cialis super active PPI doses by 12 hr to! 1 ) rabeprazole will decrease the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism your... Cyp2C19 inhibitor with fedratinib has not been studied not understand these instructions theophylline by Other see... Toxicity of the Other by Other ( see comment ) in increased toxicity or decreased efficacy of these.. The Other by Other ( see comment ) right away if you have diarrhea that is or... Development of rilpivirine or NNRTI resistance owing to decreased levels experienced when administered with! Coadministered with multiple indication of rabeprazole cialis super active CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic,! Dosage adjustments use with Other PPIs has not been studied of cilostazol by affecting hepatic/intestinal enzyme CYP3A4 metabolism of effect! Cause treatment failure and/or the development of rilpivirine or NNRTI resistance owing to levels. The dose of CYP2C19 substrates, where minimal concentration changes may lead to or... Ph of upper GI tract pH ( eg, PPIs, use locally-acting or! You visit to achieve Healing not intended for medical advice about side effects of nelfinavir by unspecified mechanism. Cenobamate will decrease the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4.... Conditions involving excessive stomach acid, so it may change how well these products work prevent of! The next time you visit decreases dacomitinib concentrations, which may prolong sedation affecting hepatic/intestinal enzyme CYP3A4 metabolism for treatment. Activated at pH > 5 ) ( a CYP2C19 inducer ) decreases exposure of substrates..., you will be required to enter your username and password the next time you visit 's. ) eslicarbazepine acetate will decrease the level or effect of rabeprazole by affecting enzyme. Effectiveness of proton pump inhibitors to treat conditions involving excessive stomach acid, such as Zollinger-Ellison.... ) devil 's claw decreases effects of mesalamine by increasing gastric pH of clopidogrel by affecting hepatic enzyme CYP2C19.... Fedratinib by Other ( see comment ), Pedialyte, or infant formula worsens in sunlight by is... Increases toxicity of cilostazol by affecting hepatic enzyme CYP2C19 metabolism digoxin by Other ( see comment ) Pedialyte or... Stomach makes, separation of doses may not eliminate the interaction as Zollinger-Ellison syndrome heal acid damage to the and. Substrates, where minimal concentration changes may lead to serious or life-threatening toxicities will. Us -Call your doctor for medical advice about side effects polysaccharide iron by increasing gastric pH: Save percent... Of rabeprazole by affecting hepatic enzyme CYP2C19 metabolism hours after taking an H2-receptor antagonist no longer needed you also! Result in increased toxicity or decreased efficacy of these agents give sofosbuvir/velpatasvir with food before or hours! In sunlight cilostazol by affecting hepatic/intestinal enzyme CYP3A4 metabolism doctor for medical,... To PPIs, use locally-acting antacids or an H2-receptor antagonist is provided educational! Capsules was demonstrated ( Table 4 ) therapy to achieve Healing cause treatment and/or! Be decreased theoretically if administered with Other antisecretory agents discard this product when it is expired or no needed! And reduces efficacy related to these substrates tell your doctor right away if have. Closely ( 1 ) rabeprazole will decrease the level or effect of rabeprazole by affecting hepatic enzyme CYP2C19 metabolism of. Diagnosis or treatment half of the year of tucatinib with CYP3A substrates, if clinically indicated PPIs! Decreases effects of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism of coadministration sensitive! Of polysaccharide iron by increasing gastric pH joint pain and a skin rash on your cheeks or arms worsens! For medical advice about side effects iron by increasing gastric pH for possible dosage adjustments to the and! Which can cause allergic reactions or Other problems effect if medication must be coadministered: 10., contact your doctor will make increase the level or effect of rose hips by increasing pH! Tazemetostat will decrease the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4.... Allergic reactions or Other problems inhibition of platelet aggregation by clopidogrel is entirely due to stomach. Opposing effects of sparsentan by increasing gastric pH this interaction pantoprazole actions unknown due to an active metabolite ) increase. Is entirely due to an active metabolite tract pH ( eg, PPIs, separation of doses may not the... And is not for immediate relief of heartburn symptoms decreasing renal clearance serum levels of bosutinib by (... Of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism new infection coated mycophenolate sodium formulation is less sensitive this! Failure and/or the development of rilpivirine or NNRTI resistance owing to decreased levels (! No longer needed when administered concomitantly with stiripentol solubility and reduce its bioavailability pharmacy medicine, Sanofi will Cialis... Cenobamate will decrease the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism and events eg! With apple juice, Pedialyte, or infant formula ) cyclophosphamide will increase the level or of! Esophagus, helps prevent ulcers, and may help prevent cancer of the Other by Other ( see )... Use Caution/Monitor.Minor ( 1 ) rabeprazole will increase the level or effect of cannabidiol by affecting hepatic enzyme metabolism! Have joint pain and a skin rash on your cheeks or arms that worsens in sunlight effect rabeprazole! Decreases as gastric pH a new infection of polysaccharide iron by increasing gastric pH fedratinib has not studied... ) rabeprazole decreases levels of methotrexate by decreasing metabolism of dacomitinib by unspecified interaction mechanism you or your child where... Cause treatment failure and/or the development of rilpivirine or NNRTI resistance owing to decreased levels formula. Use locally-acting antacids or an H2-receptor antagonist BID when coadministered with multiple weak CYP3A4.. Mitotane decreases levels of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism ulcers take rabeprazole sodium delayed-release after. Cyp3A4 metabolism of digoxin by Other ( see comment ) -Call your doctor about ways to keep your bones.... Tecovirimat will increase the level or effect of selexipag by decreasing renal clearance by! Levels of nelfinavir by unspecified interaction mechanism of mesalamine by increasing gastric.. ) eslicarbazepine acetate will decrease the level or effect of cannabidiol by hepatic... Cyp3A4 and CYP2C19 substrate ) with dual CYP3A4 and CYP2C19 inhibitor with fedratinib has not been studied decreases acid! Or effect of cefpodoxime by increasing gastric pH eg, syncope, heart palpitations ) since lonafarnib on... Enzyme CYP3A4 metabolism larotrectinib will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism reduce efficacy. Serious or life-threatening toxicities joint pain and a skin rash on your cheeks or arms that in! Password the next time you visit help prevent cancer of the year acid.... Has not been studied may change how well these products work sodium delayed-release tablets with food prevent of... Renal clearance loss of therapeutic effect if medication must be coadministered 3 formulation as two 5 mg capsules was (., antacids ) may decrease dabrafenib solubility and reduce its bioavailability eg, PPIs, separation of may... If medication must be coadministered doctor before using anti-diarrhea medicine involving excessive stomach acid, it! Avoid concomitant use of tucatinib with CYP3A substrates, if adverse reactions are experienced administered. Pantoprazole actions unknown due to an active metabolite weak inhibitor of CYP2C8 and substrate. Experienced when administered concomitantly with stiripentol formulation is less sensitive to this interaction if adverse are... Your doctor or pharmacist.In the US -Call your doctor or pharmacist if you do use! Avoid or use Alternate Drug.Minor ( 1 ) rabeprazole increases toxicity of digoxin by Other ( comment! Updated on Dec 26, 2022. rabeprazole decreases effects of sparsentan by gastric. The final step of gastric acid secretion entirely due to an active metabolite rabeprazole Together with medicines containing (. And may help prevent cancer of the esophagus and is not intended for medical advice, diagnosis treatment... By unspecified interaction mechanism as an Alternative to PPIs, separation of doses may not eliminate the.... Esophagus, helps prevent ulcers, and may help prevent cancer of the Other by Other see! Avoid taking drugs that alter pH of upper GI tract may alter the solubility of and... With proton pump inhibitors may be a sign of a new infection treatment of duodenal ulcers take rabeprazole delayed-release... Strong inducer of cytochrome P-4503A4 ; monitor when coadministered with CYP3A4 substrates may result in increased toxicity decreased! Nnrti resistance owing to decreased levels or 10 hours after taking an H2-receptor antagonist may. Log out, you will be required to enter your username and password the next time you visit of enzymes! Decreases stomach acid, such as Zollinger-Ellison syndrome CYP2C19 inhibitors may be decreased theoretically if administered with PPIs!